Interleukin-2: SILCAAT study to continue.
In late 2002, Chiron Corporation announced its decision to shut down a large pivotal study of the drug, interleukin-2 (IL-2, Proleukin). In the days and weeks following the announcement, researchers and community activists met with the company to negotiate for the SILCAAT study to continue. In February 2003, heroic efforts by non-Chiron scientists to continue this important study were successful, and a transition to the study from Chiron into independent hands was completed. The study will continue.
D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*
D007376:Interleukin-2